Antonio Cannata is an expert in Cardiology at British Heart Foundation (United Kingdom). As of October 2026, ScienceLeadR ranks Antonio Cannata in the top 1% of experts worldwide for Heart Failure and Cardiomyopathies. Antonio Cannata has authored 260 publications, the most recent in 2026, and is an investigator in 3 clinical trials. SLR score: 924 (community average: 125). How the SLR is computed.

LeadR Profile

Antonio Cannata British Heart Foundation United Kingdom
924 ScienceLeadR Reputation 924
Network Map

Cardiology

Subspecialties: Public Health - Pharmacy - Biostatistics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

I am an academic cardiologist with a special interest in heart failure and cardio-oncology. Since April 2019, I have been working at King’s College Hospital in Heart Failure and cardio-oncology.

During my PhD, I have developed academic skills in big data analysis, linking large nationwide registries (namely the National Heart Failure Audit - NHFA, HES, ONS, and CPRD). I have linked and analysed the data, exploring the quality of care of patients with heart failure over time using advanced statistical modelling, including multilevel survival models, interaction testing and non-linear survival models.

I have also established at KCL an international registry on inflammatory heart disease (the CAIR Registry) involving more than 1500 patients with confirmed myocarditis across 8 countries in 3 continents, and actively collaborate with the Epic platform to develop a streamlined pathway for clinical trials across Europe.

I have also successfully completed an MSc in Clinical Trials at the University of Oxford with a Dissertation on a non-inferiority trial of withdrawal of medical therapy in ischaemic heart disease.

Academically, I have authored >150 peer-reviewed publications (including first author publications in the New England Journal of Medicine, the Lancet, JACC, JAMA Cardiology, European Heart Journal and European Journal of Heart Failure), have won several prizes and presented my work nationally and internationally.

I am author of many publications on heart failure and cardiomyopathies, inequalities of care for patients with heart failure, and the role of heart failure specialised care during hospitalisation. I am first author of a NEJM review article on Heart Failure with Preserved Ejection Fraction and a Lancet Seminar on Heart Failure with Reduced Ejection Fraction.

I am a member of national and international societies, including the ESC council on Cardio-Oncology. I am the immediate past Chair of the HFA Young Committee overseeing international projects for >5000 young Heart Failure specialists and the Co-Chair of the ESC Young Cardiovascular professional Board Committee.

I am have supervised and mentored international fellows, medical students, and thesis discussants.


Organizations

Career arc: 2013 - 2026

Source: PubMed

King's College London

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 260

Citations

Citations: 4 426 1st author: 43 Last author: 19 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Sex-Based Differences in Chronic Heart Failure: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PMID 42876202 — heart failure, pharmaceutical preparations, heart, heart failure, diastolic, heart failure, systolic, sex, therapeutics
Eur J Heart Fail20260
"Baseline Characteristics and Utilization of Medical Therapies in Acute Hospitalized and Chronic Heart Failure Patients Enrolled in GRASP-HF: Differences Between ICARe-HF and Non-ICARe-HF Centres".
PMID 42867408 — mortality, heart failure, heart, hospital mortality, heart failure, systolic, therapeutics
Eur J Heart Fail20260
Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement.
PMID 42817848 — kidney diseases, heart failure, heart, kidney, therapeutics
Eur J Heart Fail20260
Physical activity and exercise training in patients with HFrEF - Authors' reply.
PMID 42753760 — exercise, heart failure, systolic
Lancet Top journal20260
Incidence and prevalence of Takayasu arteritis in England before and after the COVID-19 pandemic: results from RECORDER.
PMID 42626720 — epidemiology, incidence, takayasu arteritis, arteritis, covid-19, prevalence, diagnosis, pandemics
Rheumatol Adv Pract20260

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 1/Phase 2 1
Phase 2 1

By status:

Completed 3

By type:

Interventional 2
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 2

LeadR Networks

Main global connection map